glp 1 side effects eyesight Ozempic Blindness Lawsuit [2026 Update] Ozempic side effects LEAD TO

Eli Lilly announced Phase 3 ATTAIN-1 trial results for orforglipron, an oral GLP-1 receptor agonist, showing significant weight loss in adults with obesity or overweight without diabetes

It is currently approved only for type 2 diabetes mellitus (Mounjaro) and chronic weight management (Zepbound), and any potential addiction-related benefits remain investigational

For patients with contraindications to GLP-1 receptor agonists, numerous effective alternatives exist for managing type 2 diabetes and obesity

She felt she was being productive for the first time in years

Ozempic Shortage resolved Available .68 mg/1 mL 4 recent reports Shortage resolved according to the FDA but we're receiving reports of supply issues

1 These findings led researchers to develop GLP-1 drugs to lower blood glucose levels in patients with type 2 diabetes (T2D), triggering a paradigm shift in the management of the disease